IRD - Multiplikator P/S Opus Bio

The stable scientific climate in the US and the humanitarian status of Opus Genetics Inc (IRD) developments ensure predictable growth, as reflected in the current P/S ratio trend. The value 49.60 indicates the current level of this metric. Financial stability is based on strict ESG compliance and bioethics, while high market valuation is supported by unique delivery vector patents that create an insurmountable barrier for new entrants.

Opus Genetics, Inc. (IRD): Kapitalisasi marang pendapatan saka 25.10.2024 nganti 13.11.2026

Rincian analitis perusahaan Opus Genetics Inc (IRD)

- rega saham lan prakiraan rega para ahli:

Bagan kutipan opusgtx.com|IRD - Target konsensus

- statistik kapitalisasi pasar:

Kapitalisasi pasar Opus Bio|IRD - Nilai Total Perusahaan

- data ekuitas miturut neraca:

Aset Bersih saben Saham Opus Genetics|IRD - Aset Bersih Perusahaan|Nilai Pasar marang Nilai Buku opusgtx.com|IRD - Total Aset Perusahaan

- indikator beban kredit lan likuiditas emiten:

- data bathi resik lan rasio valuasi:

IRD - Bathi resik|Prakiraan bathi perusahaan Opus Genetics Inc|IRD - Pangali P/E|Prakiraan rega marang bathi opusgtx.com|IRD - Rasio rega marang bathi tumrap wutah|Rasio total nilai perusahaan marang bathi operasional sadurunge panyusutan Opus Bio|IRD - Bathi operasional sadurunge ngurangi amortisasi|Bathi saben saham sajroning taun lumaku Opus Genetics|IRD - Bathi resik saben saham (EPS TTM)|Owah-owahan bathi resik saben saham taun-ka-taun sajrone rolas wulan pungkasan opusgtx.com|IRD - Wutah bathi saben saham ing taun lumaku|Proyeksi kacepetan wutah bathi saben saham kanggo taun ngarep Opus Genetics Inc

- indikator pendapatan dodolan lan penghasilan bisnis:

IRD - Pendapatan lan volume dodolan|Volume dodolan mangsa ngarep perusahaan opusgtx.com|IRD - Multiplikator P/S|Rasio kapitalisasi marang dodolan sing dikarepake Opus Bio

Analisis fundamental perusahaan:Opus Genetics, Inc. (IRD)

Opus Genetics Inc (IRD) specializes in developing innovative gene therapy methods to combat hereditary blindness. The estimated price-to-sales ratio reflects the market value of the business relative to its actual sales. This multiple allows for an assessment of the premium paid for the future success of clinical trials and orphan drug status. It is critical for investors to benchmark this indicator against the commercialization rates of gene delivery technologies.

Perusahaan pesaing

ALC: Rasio rega marang dodolan|Bausch + Lomb - Kapitalisasi marang pendapatan|Multiplikator P/S Glaukos Corp GKOS|APLS - Rasio rega marang pendapatan|Koefisien rega marang pendapatan Belite Bio, Inc BLTE|OCUL (Ocular Therapeutix) - Kapitalisasi marang pendapatan|harrowinc.com - Rasio kapitalisasi pasar marang pendapatan|VRDN (Viridian Therapeutics, Inc.) - Multiplikator P/S|LENZ - Multiplikator rega marang pendapatan|Multiplikator P/S OCS|EYPT - Rega marang dodolan|Rasio rega marang pendapatan Kodiak Sciences Inc. KOD|ALDX: Rasio kapitalisasi marang pendapatan|Kala Pharmaceuticals - Multiplikator P/S|Rega marang dodolan OKYO Pharma Limited|ADVM (adverum.com) - Kapitalisasi marang pendapatan|OTLK: Kapitalisasi marang volume dodolan|CLSD (Clearside Biomedical) - Multiplikator P/S|NovaBay (NBY) - Koefisien rega marang pendapatan|Multiplikator P/S KPRX|Kapitalisasi marang pendapatan alimerasciences.com ALIM|Rasio rega marang pendapatan Eyenovia EYEN|Koefisien rega marang pendapatan Guardion Health (GHSI)|OCUP: Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan OPT (opthea.com)